Radiopharmaceutical company developing imaging and therapeutic products for oncology, including PSMA-PET imaging agent Illuccix and the late-stage kidney cancer imaging agent TLX250-CDx; acquiring ITM Isotope Technologies Munich to add a therapeutic pipeline and isotope supply network.
Close of $1.65B ITM Isotope Technologies Munich acquisition
Telix struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis' Lutathera and a radiopharmaceutical supply network; analysts called the move 'extremely bullish'.
Group Chief Executive Officer
Chief Executive Officer, Telix Therapeutics
Chief Executive Officer, Telix International